<DOC>
	<DOCNO>NCT00204789</DOCNO>
	<brief_summary>This double blind , placebo control study 52 patient least one-year post-solid organ transplant . Subjects receive either 12 month DFMO placebo . The specific aim determine DFMO 500 mg daily well tolerated 12 month affect organ transplant viability ; inhibit 12-O-tetradecanoylphorbol-13-acetate ( TPA ) -induced ornithine decarboxylase ( ODC ) skin biopsy approximately 50 % 12 month therapy ; able decrease polyamine level skin biopsy 12 month treatment .</brief_summary>
	<brief_title>Difluoromethylornithine ( DFMO ) Chemoprevention Skin Cancer Organ Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Eflornithine</mesh_term>
	<criteria>&gt; 1 year postsolid organ transplant kidney , liver , pancreas , pancreas/kidney Adequate organ function Hearing age/gender appropriate At high risk develop skin cancer Immunosuppressant level dose show stable graft function Use concomitant RetinA , Efudex , Accutane psoralen ultraviolet light A ( PUVA ) Systemic therapy cancer treatment prophylaxis Use concomitant azathioprine , antiseizure medication , nonsteroidal antiinflammatory drug [ NSAIDs ] ( cardioprotective dos aspirin )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>